Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 7 | 2022 | 119 | 1.250 |
Why?
|
| Prevalence | 3 | 2018 | 884 | 0.650 |
Why?
|
| Electronic Health Records | 3 | 2020 | 681 | 0.610 |
Why?
|
| Confidentiality | 1 | 2018 | 27 | 0.610 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 81 | 0.600 |
Why?
|
| Statistics as Topic | 1 | 2018 | 64 | 0.600 |
Why?
|
| Papillomavirus Infections | 4 | 2022 | 133 | 0.550 |
Why?
|
| Papillomaviridae | 5 | 2022 | 52 | 0.540 |
Why?
|
| Primary Health Care | 3 | 2024 | 766 | 0.440 |
Why?
|
| Models, Statistical | 3 | 2019 | 177 | 0.420 |
Why?
|
| Opioid-Related Disorders | 2 | 2024 | 167 | 0.390 |
Why?
|
| Cervical Intraepithelial Neoplasia | 3 | 2022 | 16 | 0.380 |
Why?
|
| Incidence | 4 | 2020 | 1255 | 0.310 |
Why?
|
| Humans | 20 | 2024 | 17611 | 0.300 |
Why?
|
| Female | 18 | 2024 | 12608 | 0.290 |
Why?
|
| Smoking | 3 | 2020 | 483 | 0.260 |
Why?
|
| Risk Assessment | 3 | 2019 | 1097 | 0.250 |
Why?
|
| Middle Aged | 14 | 2024 | 7911 | 0.250 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 501 | 0.230 |
Why?
|
| Aged | 12 | 2024 | 6095 | 0.220 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 13 | 0.200 |
Why?
|
| Adult | 11 | 2024 | 7598 | 0.200 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 358 | 0.190 |
Why?
|
| Borrelia burgdorferi | 1 | 2020 | 1 | 0.180 |
Why?
|
| Lyme Disease | 1 | 2020 | 4 | 0.180 |
Why?
|
| Bacterial Proteins | 1 | 2020 | 13 | 0.180 |
Why?
|
| Telephone | 1 | 2021 | 161 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2020 | 29 | 0.180 |
Why?
|
| Patient Participation | 1 | 2021 | 133 | 0.180 |
Why?
|
| Likelihood Functions | 1 | 2020 | 44 | 0.180 |
Why?
|
| Prognosis | 2 | 2019 | 606 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2020 | 83 | 0.170 |
Why?
|
| Hospitals, Teaching | 1 | 2018 | 17 | 0.160 |
Why?
|
| Mass Screening | 3 | 2022 | 661 | 0.160 |
Why?
|
| Gastrectomy | 1 | 2018 | 46 | 0.160 |
Why?
|
| Human Papillomavirus DNA Tests | 1 | 2018 | 1 | 0.160 |
Why?
|
| Cervix Uteri | 1 | 2018 | 5 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 41 | 0.150 |
Why?
|
| Sampling Studies | 1 | 2018 | 51 | 0.150 |
Why?
|
| Telemedicine | 1 | 2021 | 182 | 0.150 |
Why?
|
| Inpatients | 1 | 2018 | 81 | 0.150 |
Why?
|
| Biomarkers | 2 | 2019 | 301 | 0.150 |
Why?
|
| Cluster Analysis | 1 | 2018 | 89 | 0.150 |
Why?
|
| Male | 9 | 2024 | 10008 | 0.150 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 22 | 0.150 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 50 | 0.150 |
Why?
|
| Logistic Models | 2 | 2017 | 926 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 42 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2017 | 53 | 0.140 |
Why?
|
| Health Surveys | 1 | 2018 | 260 | 0.140 |
Why?
|
| Occupations | 1 | 2016 | 16 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2017 | 215 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 153 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2017 | 51 | 0.140 |
Why?
|
| Occupational Exposure | 1 | 2016 | 67 | 0.130 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 56 | 0.130 |
Why?
|
| Lung Diseases | 1 | 2016 | 42 | 0.130 |
Why?
|
| Algorithms | 1 | 2017 | 233 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 1900 | 0.130 |
Why?
|
| Lung | 1 | 2016 | 62 | 0.130 |
Why?
|
| Radiographic Image Enhancement | 1 | 2014 | 3 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 7 | 0.120 |
Why?
|
| Indians, North American | 1 | 2014 | 49 | 0.120 |
Why?
|
| Vaginal Smears | 3 | 2022 | 48 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 244 | 0.120 |
Why?
|
| Opiate Substitution Treatment | 2 | 2024 | 44 | 0.120 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 529 | 0.110 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 1322 | 0.110 |
Why?
|
| Mammography | 1 | 2014 | 169 | 0.110 |
Why?
|
| African Americans | 1 | 2016 | 472 | 0.110 |
Why?
|
| United States | 5 | 2020 | 3956 | 0.100 |
Why?
|
| Heart Failure | 1 | 2017 | 396 | 0.100 |
Why?
|
| Risk Factors | 5 | 2017 | 3325 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2008 | 74 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2008 | 91 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 748 | 0.070 |
Why?
|
| Triage | 2 | 2016 | 15 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 304 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 949 | 0.070 |
Why?
|
| Nursing Care | 1 | 2024 | 4 | 0.060 |
Why?
|
| Probability | 2 | 2019 | 79 | 0.060 |
Why?
|
| Massachusetts | 1 | 2024 | 93 | 0.060 |
Why?
|
| Buprenorphine | 1 | 2024 | 48 | 0.060 |
Why?
|
| Videoconferencing | 1 | 2021 | 7 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2021 | 26 | 0.050 |
Why?
|
| California | 2 | 2017 | 2284 | 0.050 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 1 | 0.050 |
Why?
|
| Bacterial Load | 1 | 2020 | 3 | 0.050 |
Why?
|
| Gene Library | 1 | 2020 | 3 | 0.050 |
Why?
|
| SEER Program | 1 | 2020 | 91 | 0.050 |
Why?
|
| Mice | 1 | 2020 | 68 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 382 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 2570 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 128 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 259 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 5 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 516 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2019 | 81 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 797 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2018 | 145 | 0.040 |
Why?
|
| Genotype | 1 | 2018 | 227 | 0.040 |
Why?
|
| Young Adult | 1 | 2024 | 2427 | 0.040 |
Why?
|
| Blood Urea Nitrogen | 1 | 2017 | 8 | 0.040 |
Why?
|
| Papanicolaou Test | 1 | 2017 | 37 | 0.040 |
Why?
|
| Creatinine | 1 | 2017 | 65 | 0.040 |
Why?
|
| Kidney | 1 | 2017 | 52 | 0.040 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 3 | 0.040 |
Why?
|
| Colposcopy | 1 | 2016 | 4 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2017 | 92 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2016 | 7 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 74 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 250 | 0.030 |
Why?
|
| Adolescent | 1 | 2024 | 3651 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2016 | 69 | 0.030 |
Why?
|
| Spirometry | 1 | 2016 | 65 | 0.030 |
Why?
|
| Phosphatidylcholines | 1 | 2014 | 1 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2014 | 6 | 0.030 |
Why?
|
| Metabolomics | 1 | 2014 | 8 | 0.030 |
Why?
|
| Isoflavones | 1 | 2014 | 14 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2014 | 10 | 0.030 |
Why?
|
| Fasting | 1 | 2014 | 48 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 5 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 13 | 0.030 |
Why?
|
| Obesity | 1 | 2020 | 837 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2014 | 133 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 643 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2020 | 2447 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 710 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 917 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 1210 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2014 | 1267 | 0.020 |
Why?
|
| Korea | 1 | 2008 | 9 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2008 | 50 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 297 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 568 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 1309 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2008 | 958 | 0.010 |
Why?
|
Concepts
(137)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(3)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->